1,142
Views
0
CrossRef citations to date
0
Altmetric
Original Articles

Role of anti-TNF in Pediatric Inflammatory Choroidal Neovascularization: A Case Series

, MD, , MD, , MD, , MD, , MD, , MD, , MD & , MD show all
Pages 1006-1012 | Received 22 Sep 2021, Accepted 18 May 2022, Published online: 08 Jun 2022

References

  • Ganesh SK, Ahmed AS. Pediatric inflammatory CNV: a case series from a tertiary referral centre. Ocul Immunol Inflamm. 2020 Jan 2;28(1):26–32. doi:10.1080/09273948.2019.1576909.
  • Moosajee M, Abbouda A, Foot B, Bunce C, Moore AT, Acheson J. Active surveillance of choroidal neovascularisation in children: incidence, aetiology and management findings from a national study in the UK. British J Ophthalmol. 2018 Apr 1;102(4):438–443. doi:10.1136/bjophthalmol-2017-310445.
  • Barth T, Zeman F, Helbig H, Oberacher-Velten I. Etiology and treatment of choroidal neovascularization in pediatric patients. Eur J Ophthalmol. 2016 Sep;26(5):388–393. doi:10.5301/ejo.5000820.
  • Rishi P, Gupta A, Rishi E, Shah BJ. Choroidal neovascularization in 36 eyes of children and adolescents. Eye. 2013 Oct;27(10):1158–1168. doi:10.1038/eye.2013.155.
  • Padhi TR, Anderson BJ, Abbey AM, et al. Choroidal neovascular membrane in paediatric patients: clinical characteristics and outcomes. British J Ophthalmol. 2018 Sep 1;102(9):1232–1237. doi:10.1136/bjophthalmol-2017-310497.
  • Kramer M, Axer-Siegel R, Jaouni T, et al. Bevacizumab for choroidal neovascularization related to inflammatory diseases. Retina. 2010 Jun 1;30(6):938–944. doi:10.1097/IAE.0b013e3181c96a00.
  • Finn AP, Fujino D, Lum F, Rao P. Etiology, treatment patterns, and outcomes for choroidal neovascularization in the pediatric population: an intelligent research in sight (IRIS®) registry study. Ophthalmol Retina. 2022 Feb 1;6(2):130–138. doi:10.1016/j.oret.2021.05.015.
  • Neri P, Lettieri M, Fortuna C, Manoni M, Giovannini A. Inflammatory choroidal neovascularization. Middle East Afr J Ophthalmol. 2009 Oct;16(4):245. doi:10.4103/0974-9233.58422.
  • Kohly RP, Muni RH, Kertes PJ, Lam WC. Management of pediatric choroidal neovascular membranes with intravitreal anti-VEGF agents: a retrospective consecutive case series. Can J Ophthalmol. 2011 Feb 1;46(1):46–50. doi:10.3129/i10-123.
  • Kang HG, Choi EY, Byeon SH, et al. Anti-vascular endothelial growth factor treatment of retinopathy of prematurity: efficacy, safety, and anatomical outcomes. Korean J Ophthalmol. 2018 Dec 1;32(6):451–458. doi:10.3341/kjo.2018.0011.
  • Kozak I, Mansour A, Diaz RI, et al. Outcomes of treatment of pediatric choroidal neovascularization with intravitreal antiangiogenic agents: the results of the KKESH international collaborative retina study group. Retina. 2014 Oct 1;34(10):2044–2052. doi:10.1097/IAE.0000000000000200.
  • Flaxel CJ, Owens SL, Mulholland B, Schwartz SD, Gregor ZJ. The use of corticosteroids for choroidal neovascularisation in young patients. Eye. 1998 Mar;12(2):266–272. doi:10.1038/eye.1998.62.
  • Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 1985 Dec 20;230(4732):1375–1378. doi:10.1126/science.2416056.
  • Folkman JU, Ingber DE. Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg. 1987 Sep;206(3):374. doi:10.1097/00000658-198709000-00016.
  • Dees C, Arnold JJ, Forrester JV, Dick AD. Immunosuppressive treatment of choroidal neovascularization associated with endogenous posterior uveitis. Arch Ophthalmol. 1998 Nov 1;116(11):1456–1461. doi:10.1001/archopht.116.11.1456.
  • Sood AB, Angeles-Han ST. An update on treatment of pediatric chronic non-infectious uveitis. Current Treat Options Rheumatol. 2017 Mar 1;3(1):1–6. doi:10.1007/s40674-017-0057-z.
  • Ramanan AV, Dick AD, Guly C, et al. Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatol. 2020 Mar 1;2(3):e135–41. doi:10.1016/S2665-9913(20)30008-4.
  • Fabiani C, Vitale A, Rigante D, et al. Comparative efficacy between Adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clin Rheumatol. 2019 Feb 14;38(2):407–415. doi:10.1007/s10067-018-4228-6.
  • Aardoom MA, Veereman G, de Ridder L. A review on the use of Anti-TNF in children and adolescents with inflammatory bowel disease. Int J Mol Sci. 2019 Jan;20(10):2529. doi:10.3390/ijms20102529.
  • Ho M, Chen LJ, Sin HP, et al. Experience of using Adalimumab in treating sight-threatening paediatric or adolescent Behcet’s disease-related uveitis. J Ophthalmic Inflamm Infect. 2019 Dec;9(1):1–7. doi:10.1186/s12348-019-0181-z.
  • Iborra M, Beltrán B, Bastida G, Aguas M, Nos P. Infliximab and Adalimumab-induced psoriasis in Crohn’s disease: a paradoxical side effect. J Crohn’s Colitis. 2011 Apr 1;5(2):157–161. doi:10.1016/j.crohns.2010.11.001.